ARTICLE | Company News
EC approves Opdivo for advanced melanoma
June 20, 2015 1:00 AM UTC
Bristol-Myers Squibb Co. (NYSE:BMY) said the European Commission approved an MAA for Opdivo nivolumab for first-line and previously treated patients with advanced unresectable or metastatic melanoma, regardless of BRAF status. Opdivo is the first PD-1 inhibitor approved in the EU. BMS spokesperson Carrie Fernandez said the company expects to launch Opdivo in Europe within a week. ...